RENEU-HF — JK07 for Chronic Heart Failure
Chronic Heart Failure
Sponsor: Salubris Biotherapeutics (JK07 Bio) · JK07.2.01 · NCT06369298
About this study
Phase 2 RENEU-HF study of JK07, an investigational neuregulin-1 fusion protein for chronic heart failure.
To evaluate the safety and effect of JK07 — a novel neuregulin-1 fusion protein — in adults with chronic heart failure.
Study details
- Sponsor
- Salubris Biotherapeutics (JK07 Bio)
- Protocol
- JK07.2.01
- Phase
- Phase 2
- Indication
- Chronic Heart Failure
- Status
- Currently Recruiting
High-level eligibility
- Adults 18–85 with chronic heart failure
- NYHA Class II–III symptoms
- On stable guideline-directed medical therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.